Last Updated : July 28, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Idhifa | Enasidenib | Acute myeloid leukemia (AML) | Do not reimburse | Complete | ||
| Ikervis | cyclosporine | keratitis, severe | Withdrawn | |||
| Ilaris | Canakinumab | Cryopyrin-Associated Periodic Syndrome | Do not list | Complete | ||
| Ilaris | Canakinumab | Systemic Juvenile Idiopathic Arthritis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Ilumya | tildrakizumab | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete | ||
| Iluvien | fluocinolone acetonide | Diabetic macular edema (DME) | Withdrawn | |||
| Iluvien | fluocinolone acetonide intravitreal implant | diabetic macular edema | Do not reimburse | Complete | ||
| Imbruvica | Ibrutinib | Waldenstrom's Macroglobulinemia | Do not reimburse | Complete | ||
| Imbruvica | ibrutinib | Leukemia | Canada’s Drug Agency is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
| Imbruvica | Ibrutinib | Chronic Lymphocytic Leukemia (previously untreated) | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : July 28, 2024